Cost-utility analysis of interferon-free treatments for patients with early-stage genotype 1 hepatitis C virus in Brazil

INTRODUCTION: We conducted a cost-utility analysis of available interferon-free treatments for patients with early-stage genotype 1 chronic hepatitis C based on a Brazilian public health system perspective. METHODS: A Markov model was derived using a cohort of stage F0-F2 patients treated as recomme...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferreira, Vinicius Lins, Leonart, Leticia Paula, Pedroso, Maria Lucia Alves, Pontarolo, Roberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedade Brasileira de Medicina Tropical - SBMT 2020
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7310368/
https://www.ncbi.nlm.nih.gov/pubmed/32578707
http://dx.doi.org/10.1590/0037-8682-0594-2019
_version_ 1783549355797512192
author Ferreira, Vinicius Lins
Leonart, Leticia Paula
Pedroso, Maria Lucia Alves
Pontarolo, Roberto
author_facet Ferreira, Vinicius Lins
Leonart, Leticia Paula
Pedroso, Maria Lucia Alves
Pontarolo, Roberto
author_sort Ferreira, Vinicius Lins
collection PubMed
description INTRODUCTION: We conducted a cost-utility analysis of available interferon-free treatments for patients with early-stage genotype 1 chronic hepatitis C based on a Brazilian public health system perspective. METHODS: A Markov model was derived using a cohort of stage F0-F2 patients treated as recommended by the Brazilian national guidelines. RESULTS: Glecaprevir plus pibrentasvir was superior to all other treatments, followed by sofosbuvir plus velpatasvir. Sofosbuvir plus daclatasvir was identified as the least cost-effective option. CONCLUSIONS: The above findings were confirmed via probabilistic sensitivity analysis and the tested scenarios.
format Online
Article
Text
id pubmed-7310368
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Sociedade Brasileira de Medicina Tropical - SBMT
record_format MEDLINE/PubMed
spelling pubmed-73103682020-06-24 Cost-utility analysis of interferon-free treatments for patients with early-stage genotype 1 hepatitis C virus in Brazil Ferreira, Vinicius Lins Leonart, Leticia Paula Pedroso, Maria Lucia Alves Pontarolo, Roberto Rev Soc Bras Med Trop Short Communication INTRODUCTION: We conducted a cost-utility analysis of available interferon-free treatments for patients with early-stage genotype 1 chronic hepatitis C based on a Brazilian public health system perspective. METHODS: A Markov model was derived using a cohort of stage F0-F2 patients treated as recommended by the Brazilian national guidelines. RESULTS: Glecaprevir plus pibrentasvir was superior to all other treatments, followed by sofosbuvir plus velpatasvir. Sofosbuvir plus daclatasvir was identified as the least cost-effective option. CONCLUSIONS: The above findings were confirmed via probabilistic sensitivity analysis and the tested scenarios. Sociedade Brasileira de Medicina Tropical - SBMT 2020-06-22 /pmc/articles/PMC7310368/ /pubmed/32578707 http://dx.doi.org/10.1590/0037-8682-0594-2019 Text en https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License
spellingShingle Short Communication
Ferreira, Vinicius Lins
Leonart, Leticia Paula
Pedroso, Maria Lucia Alves
Pontarolo, Roberto
Cost-utility analysis of interferon-free treatments for patients with early-stage genotype 1 hepatitis C virus in Brazil
title Cost-utility analysis of interferon-free treatments for patients with early-stage genotype 1 hepatitis C virus in Brazil
title_full Cost-utility analysis of interferon-free treatments for patients with early-stage genotype 1 hepatitis C virus in Brazil
title_fullStr Cost-utility analysis of interferon-free treatments for patients with early-stage genotype 1 hepatitis C virus in Brazil
title_full_unstemmed Cost-utility analysis of interferon-free treatments for patients with early-stage genotype 1 hepatitis C virus in Brazil
title_short Cost-utility analysis of interferon-free treatments for patients with early-stage genotype 1 hepatitis C virus in Brazil
title_sort cost-utility analysis of interferon-free treatments for patients with early-stage genotype 1 hepatitis c virus in brazil
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7310368/
https://www.ncbi.nlm.nih.gov/pubmed/32578707
http://dx.doi.org/10.1590/0037-8682-0594-2019
work_keys_str_mv AT ferreiraviniciuslins costutilityanalysisofinterferonfreetreatmentsforpatientswithearlystagegenotype1hepatitiscvirusinbrazil
AT leonartleticiapaula costutilityanalysisofinterferonfreetreatmentsforpatientswithearlystagegenotype1hepatitiscvirusinbrazil
AT pedrosomarialuciaalves costutilityanalysisofinterferonfreetreatmentsforpatientswithearlystagegenotype1hepatitiscvirusinbrazil
AT pontaroloroberto costutilityanalysisofinterferonfreetreatmentsforpatientswithearlystagegenotype1hepatitiscvirusinbrazil

Ejemplares similares